DUBLIN–(BUSINESS WIRE)–The “Insulin Like Growth Factor II – Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) pipeline Target constitutes close to 7 molecules. Out of which approximately 2 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II stages are 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular and Central Nervous System which include indications Acute Ischemic Stroke, Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, Breast Cancer, Huntington Disease, Metastatic Breast Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Multiple Sclerosis, Non-Small Cell Lung Cancer, Parkinson’s Disease and Solid Tumor.
The latest report Insulin Like Growth Factor II – Pipeline Review, H2 2019, outlays comprehensive information on the Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics development with respective active and dormant or discontinued projects.
Scope
- The report provides a snapshot of the global therapeutic landscape for Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2)
- The report reviews Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Key Topics Covered:
- Introduction
- Report Coverage
- Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) – Overview
- Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) – Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) – Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) – Companies Involved in Therapeutics Development
- Boehringer Ingelheim International GmbH
- Genervon Biopharmaceuticals LLC
- Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) – Drug Profiles
- GM-6 – Drug Profile
- M-610.27 – Drug Profile
- M-630 – Drug Profile
- Recombinant Protein to Inhibit IGF-1 and IGF-2 for Breast Cancer – Drug Profile
- Recombinant Proteins to Inhibit IGF-2 for Oncology – Drug Profile
- Small Molecules to Inhibit IGF-2 for Oncology – Drug Profile
- xentuzumab – Drug Profile
- Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) – Dormant Products
- Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) – Discontinued Products
- Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) – Product Development Milestones
- Featured News & Press Releases
- Feb 26, 2018: Genervon Presents Innovative CNS Drug Candidate at 2018 BIO CEO & Investor Conference
- Dec 08, 2017: GM604 Is a Multi-Target Regulator That Provides a Novel Treatment Strategy for ALS
- Mar 23, 2017: Confidential Data from Genervon ALS Phase 2A Clinical Trial Were Released and Published
- Jan 10, 2017: Genervon Releases ALS, PD and AD Disease Associated Gene Lists Modulated by GM6 and Encourages Researchers to Explore New Discoveries beyond Single Target Drug Development Paradigm
- Dec 27, 2016: ALS and Alzheimer’s disease bioinformatics reports confirm GM6’s role as regulator of disease-relevant pathways
- Jun 06, 2016: GENERVON GM604 received EUs orphan drug designation to treat ALS
- May 23, 2016: ALS Patients from Around the World Responding Well to Genervons GM604
- May 03, 2016: GM604 to Be Granted Orphan Drug Status in Europe
- Sep 22, 2015: Genervon GM604 Reduced TDP-43 Protein Aggregates and Slowed Down ALS Progression
- Jun 29, 2015: Genervon Filed Patent for Using GM604 Modulations of ALS Disease Biomarkers Showing Homeostasis, Leading to Prognosis and Therapeutic Treatment for ALS Disease
- Apr 17, 2015: Amyotrophic Lateral Sclerosis Statement; FDA
- Jan 08, 2015: Genervon Announces ALS Compassionate Use Results
- Oct 19, 2014: Genervon Announces ALS and PD Phase 2a Trial Results
- Jun 30, 2014: Genervon Announces Biomarker Data from GALS-001 Clinical Trial for ALS
- Apr 28, 2014: Genervon Successfully Completes its Phase 2a Clinical Trial for ALS
Companies Mentioned
- Boehringer Ingelheim International GmbH
- Genervon Biopharmaceuticals LLC
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/nlfww2
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900